Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Código da empresaVCYT
Nome da EmpresaVeracyte Inc
Data de listagemOct 30, 2013
CEOMr. Marc A. Stapley
Número de funcionários824
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 30
Endereço6000 Shoreline Court, Suite 300
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94080
Telefone16502436300
Sitehttps://www.veracyte.com/
Código da empresaVCYT
Data de listagemOct 30, 2013
CEOMr. Marc A. Stapley
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados